8 Feb
2019

The US’s first all biosimilar patent suit shows new pharma IP landscape is emerging

Coherus launched Delaware action against Amgen in what is likely to become an increasingly familiar life sciences litigation scenario.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth